Project Grant R44CA291290
Award Date
9/20/24
Completion Date
8/31/26
Dollars Obligated
$822K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...
The National Cancer Institute (NCI) awarded a $398,738 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Pre-Cancer Diagnosis, LLC to develop a highly sensitive DNA hypermethylation-based diagnostic kit to identify patients with Barrett's esophagus (BE) who are at high risk of progressing to esophageal adenocarcinoma (EAC). The grant aims to validate the company's preliminary findings on using DNA methylation biomarkers to differentiate high-risk and...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business in Palo Alto, California. The grant supports the development of a novel assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using orphan non-coding RNA (oncRNA) biomarkers. The goal is to create a liquid biopsy-based diagnostic...
The National Human Genome Research Institute (NHGRI) awarded a $406,500 Project Grant (CFDA 93.172 - Human Genome Research) to JBS Science Inc. to develop a urine-based liquid biopsy assay for comprehensive genetic characterization of non-muscle-invasive bladder cancer (NMIBC). The project aims to create a bladder cancer-targeted, hybridization-based next-generation sequencing (NGS) assay and data analysis pipeline to distinguish NMIBC from muscle-invasive bladder cancer (MIBC), guide disease...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
This Project Grant award of $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel, non-invasive urine-based screening test for early detection of kidney cancer. The project aims to: Demonstrate the specificity and accuracy of a biomarker for detecting early-stage renal tumors in kidney cancer patients without symptoms. Demonstrate the effectiveness and accuracy of the test for detecting residual...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...